113 results
8-K
EX-10.1
NMTRQ
9 Meters Biopharma, Inc.
18 Jul 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
NMTRQ
9 Meters Biopharma, Inc.
30 May 23
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
4:11pm
8-K
EX-10.1
NMTRQ
9 Meters Biopharma, Inc.
19 May 23
Entry into a Material Definitive Agreement
8:02am
8-K
EX-10.1
NMTRQ
9 Meters Biopharma, Inc.
27 Apr 23
Entry into a Material Definitive Agreement
8:17am
10-K
2022 FY
EX-10.30
NMTRQ
9 Meters Biopharma, Inc.
Annual report
28 Mar 23
8:07am
8-K
EX-10.1
n22xdz
15 Mar 23
9 Meters Biopharma Announces $5 Million Registered Direct Offering
4:08pm
8-K
EX-10.1
qqdxs2ijslzk6r8 sxsp
13 Jan 23
Entry into a Material Definitive Agreement
9:05am
8-K
EX-10.1
0c9nr1m7iv ov
6 Oct 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.2
648g542nic9xm9668rni
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
EX-10.1
kpbmf
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
EX-10.1
taftpd7
22 Jun 22
Departure of Directors or Certain Officers
4:51pm
8-K
EX-10.2
scy3a8v7gzi8yy7at6i
22 Jun 22
Departure of Directors or Certain Officers
4:51pm
8-K
EX-10.1
85u ll73b
18 Jan 22
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
8:05am
8-K
EX-10.2
4znxc82p dilz5ny
18 Jan 22
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
8:05am
8-K
EX-10.1
oryf143tw m615h3o
27 Nov 20
Departure of Directors or Certain Officers
4:07pm